Cisplatin-based drug combinations are now currently investigated in an attempt to surpass the results obtainable by 5-FU alone or by 5-FU-containing regimens. We evaluated 29 patients with advanced and measurable gastric adenocarcinoma treated with etoposide, epirubicin and cisplatin. One patient had complete response (3±7%); 9 patients had partial response (31±17%); 5 patients (17±14%) were considered stable (S) and 14 (48±18%) were classified as progressive. The average survival time for the entire group was 11 months with 25% of the patients alive at 24 months. We feel that cisplatin-containing regimens are promising and deserve further investigations. To clearly explore the potential innovative role of these regimens randomized trials versus FAM or 5-FU alone are mandatory.
|Number of pages||3|
|Publication status||Published - 1991|
- Gastric cancer
ASJC Scopus subject areas
- Cancer Research